Actualités et vidéos - CONCERT PHARMACEUTICALS INC.

Sun Pharma Completes Acquisition of Concert Pharmaceuticals PR Newswire MUMBAI, India and PRINCETON, N.J., March 6, 2023 Acquisition Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, to Sun Pharma's Global Dermatology Portfolio MUMBAI, India and PRINCETON, N.J. , March 6, 2023 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or...

Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment of adult patients with moderate to severe alopecia areata. In light of the FDA approval of a different JAK inhibitor as the first treatment for alopecia areata, the...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders. Per the terms of the agreement, Sun Pharma would acquire Concert for an upfront payment of $8.00 per share in cash, plus a non-tradeable contingent value right entitling Concert shareholders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net...

Sun Pharma entend acquérir Concert Pharmaceuticals pour faire progresser le traitement potentiel de l'alopécie areata PR Newswire MUMBAI, Inde et LEXINGTON, Massachusetts, 24 janvier 2023 Ajoute à son portefeuille le deuruxolitinib, un inhibiteur oral des Janus kinases qui pourrait être le meilleur de sa catégorie pour le traitement de l'alopécie areata, une maladie dermatologique auto-immune S'appuie sur l'infrastructure mondiale de Sun Pharma pour offrir un large accès au deuruxolitinib...

Sun Pharma adquirirá Concert Pharmaceuticals para avanzar en el posible tratamiento de la alopecia areata PR Newswire MUMBAI, INDIA y LEXINGTON, Massachussetts, 23 de enero de 2023 Agrega deuruxolitinib, el mejor inhibidor oral de JAK de su clase para el tratamiento de la alopecia areata, una enfermedad dermatológica autoinmune Aprovecha la infraestructura mundial de Sun Pharma para proporcionar un amplio acceso al deuruxolitinib para pacientes con alopecia areata Fortalece la franquicia...

Sun Pharma adquiere Concert Pharmaceuticals para avanzar en el tratamiento de la alopecia areata PR Newswire MUMBAI, India y LEXINGTON, Mass., 23 de enero de 2023 Añade deuruxolitinib, un inhibidor oral de JAK potencialmente mejor de su clase para el tratamiento de la alopecia areata, una enfermedad dermatológica autoinmune Aprovecha la infraestructura mundial de Sun Pharma para proporcionar un amplio acceso a deuruxolitinib a los pacientes con alopecia areata Refuerza la franquicia mundial de...

Sun Pharma erwirbt Concert Pharmaceuticals und treibt damit die Behandlung von Alopecia areata voran PR Newswire MUMBAI, Indien und LEXINGTON, Massachussetts, 23. Januar 2023 Dadurch wird Deuruxolitinib, ein potenziell klassenbester oraler JAK-Inhibitor zur Behandlung von Alopecia areata, einer autoimmunen dermatologischen Erkrankung, aufgenommen Sun Pharmas globale Infrastruktur wird genutzt, um Patienten mit Alopecia areata einen breiten Zugang zu Deuruxolitinib zu ermöglichen Das globale...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Concert Pharmaceuticals, Inc. (NasdaqGM: CNCE) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Concert will receive $8.00 in cash plus one contingent value right (CVR) (entitling its holder to receive up to an additional $3.50 per share of common stock in cash upon achieving certain net...

SHAREHOLDER ALERT: Weiss Law Investigates Concert Pharmaceuticals, Inc. PR Newswire NEW YORK, Jan. 19, 2023 NEW YORK , Jan. 19, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Concert Pharmaceuticals, Inc. ("Concert" or the "Company") (NASDAQ: CNCE), in connection with the proposed acquisition of the Company by Sun Pharmaceutical Industries Limited via tender offer. Under the terms of the merger...

Shareholder Alert: Ademi LLP investigates whether Concert Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Sun Pharma PR Newswire MILWAUKEE, Jan. 19, 2023 MILWAUKEE , Jan. 19, 2023 /PRNewswire/ -- Ademi LLP is investigating Concert (NASDAQ: CNCE) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma. Click here to learn how to join the action https://www.ademilaw.com/case/concert-pharmaceuticals-inc or call Guri Ademi...

Thinking about buying stock in Concert Pharmaceuticals, Transocean, Faraday Future Intelligent Electric, Marathon Digital, or Affirm? PR Newswire NEW YORK, Jan. 19, 2023 NEW YORK , Jan. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNCE, RIG, FFIE, MARA, and AFRM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CNCE:...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) to Sun Pharmaceutical Industries Limited is fair to Concert shareholders. Per the terms of the agreement, Sun Pharma would acquire Concert for an upfront payment of $8.00 per share in cash, plus a non-tradeable contingent value right entitling Concert shareholders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net...

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata PR Newswire MUMBAI, India and LEXINGTON, Mass., Jan. 19, 2023 Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage...

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata PR Newswire MUMBAI, India and LEXINGTON, Mass., Jan. 19, 2023 Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage...

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata PR Newswire MUMBAI, India and LEXINGTON, Mass., Jan. 19, 2023 Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, “Sun Pharma”)) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (“Concert”) today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the presentation of data from its THRIVE-AA1 Phase 3 clinical trial during the 12 th World Congress for Hair Research. The presentation highlights THRIVE-AA1 study results evaluating Concert’s investigational oral medicine deuruxolitinib (CTP-543) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss. The World Congress presentation includes new analyses...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT. A webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com . A replay will be available on Concert’s website for two weeks following the presentation. About Concert Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2022. “With the THRIVE-AA clinical program completed and positive Phase 3 results in hand for deuruxolitinib in alopecia areata, we are well on our way to meeting our goal of submitting the NDA in the first half of 2023,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “Given the promising clinical properties and potential best-in-class profile...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the third quarter of 2022, on Monday, November 7, 2022, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss its third quarter 2022 financial results and provide a business update. To join the live call to ask questions, please register here . A dial in and unique PIN will be provided to join the call. An audio-only webcast...